Order Article Reprints

Daido W, Masuda T, Imano N, Matsumoto N, Hamai K, Iwamoto Y, Takayama Y, Ueno S, Sumii M, Shoda H, et al. Pre-Existing Interstitial Lung Abnormalities Are Independent Risk Factors for Interstitial Lung Disease during Durvalumab Treatment after Chemoradiotherapy in Patients with Locally Advanced Non-Small-Cell Lung Cancer. Cancers. 2022; 14(24):6236. https://doi.org/10.3390/cancers14246236

Daido, Wakako, Takeshi Masuda, Nobuki Imano, Naoko Matsumoto, Kosuke Hamai, Yasuo Iwamoto, Yusuke Takayama, Sayaka Ueno, Masahiko Sumii, Hiroyasu Shoda, and et al. 2022. "Pre-Existing Interstitial Lung Abnormalities Are Independent Risk Factors for Interstitial Lung Disease during Durvalumab Treatment after Chemoradiotherapy in Patients with Locally Advanced Non-Small-Cell Lung Cancer" Cancers 14, no. 24: 6236. https://doi.org/10.3390/cancers14246236

Daido, W., Masuda, T., Imano, N., Matsumoto, N., Hamai, K., Iwamoto, Y., Takayama, Y., Ueno, S., Sumii, M., Shoda, H., Ishikawa, N., Yamasaki, M., Nishimura, Y., Kawase, S., Shiota, N., Awaya, Y., Suzuki, T., Kitaguchi, S., Fujitaka, K., ... Hattori, N. (2022). Pre-Existing Interstitial Lung Abnormalities Are Independent Risk Factors for Interstitial Lung Disease during Durvalumab Treatment after Chemoradiotherapy in Patients with Locally Advanced Non-Small-Cell Lung Cancer. Cancers, 14(24), 6236. https://doi.org/10.3390/cancers14246236